A.-R. Hanauske

Reproducibility of metabolic measurements in malignant tumors using FDG PET.

Wolfgang Weber, Sibylle Ziegler, R. Thödtmann et al. · PubMed · 1999 · 394 citations

Immunoreactive alpha transforming growth factor activity in effusions from cancer patients as a marker of tumor burden and patient prognosis.

Carlos L. Arteaga, A.-R. Hanauske, Gary M. Clark et al. · PubMed · 1988 · 91 citations

Alpha-tgf Activity, Immunology, Pathology +18

Application of a New Multinomial Phase II Stopping Rule Using Response and Early Progression

Susan Dent, Benny Zee, Janet Dancey et al. · Journal of Clinical Oncology · 2001 · 77 citations

Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: Comparison with taxol and conventional antineoplastic agents

Marianne Vogel, Susan G. Hilsenbeck, H. Depenbrock et al. · European Journal of Cancer · 1993 · 44 citations

Tumor Biology, Oncology, Malignant Disease +9

Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin’s lymphoma – phase I/II studies and pharmacokinetics

Jan Braess, Mathias Freund, A.-R. Hanauske et al. · Leukemia · 1998 · 31 citations

Hematological Malignancy, Oncology, Oral Cytarabine Ocfosfate +7